Apimeds Pharmaceuticals US Inc. (APUS) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, APUS scores 37 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 8 / 20. The rating cites ROIC of -6.2% and an FCF yield of 0%. For a prospective investor, this indicates the business is not currently generating returns on invested capital or free cash flow to support valuation on a cash-earnings basis.
• Whale 13F Flow: 3 / 20. Covers institutional accumulation and options positioning. This is the weakest pillar and suggests limited evidence of sophisticated-holder conviction in the source data.
• Insider Conviction: 5 / 20. Covers SEC Form 4 and Congressional PTR cluster flow. A low score here means the source does not show meaningful insider buying conviction.
• Macro Regime Fit: 11 / 20. Reflects beta of 1.0 and sector sensitivity. The stock moves in line with the market on this measure, offering no defensive cushion.
• Forensic Balance Sheet: 10 / 20. Cites Altman Z-Score of 2.5, Piotroski F-Score of 1/9, and Debt/Equity of 0.5. The weak Piotroski reading is the key concern for an investor assessing financial health.

Upside drivers, as suggested by the rating's framework, would require improvement in cash generation and institutional or insider participation. The valuation tradeoff is that the market cap of $5.0M and share price of $3.21 sit against negative operating and net income in the reported periods, leaving little earnings-based valuation support in the source data. Investors should weigh the explicit "Sell" classification against any short-term price momentum visible in the news wire.

Per the SEC financials, reported revenue is $0.0M in each period and operating and net losses widened from FY 2023 to FY 2025, with FY 2025 operating loss at $-11.9M. Gross, operating, and net margins are each listed as 0% in market data. ROIC is -6.2%. The Roarable RQD rating cites an Altman Z-Score of 2.5 and a Piotroski F-Score of 1/9, with Debt/Equity of 0.5. Cash of $1.6M at FY 2025 is small relative to the $-9.0M free cash flow reported for the same year.

Per the recent news feed, all six items relate to APUS market action, with no specific product, regulatory, or clinical catalyst named in the headlines or summaries:

• Benzinga, "Why Is Apimeds Pharmaceuticals Stock Gaining Monday?" (1h ago, GREEN, CATALYST)
• kalkine.ca, "Why Did Apimeds (NYSEAMERICAN:APUS) Jump 55.3% After 42.5%?" (3h ago, GREEN, CATALYST)
• Timothy Sykes, "APUS Stock Whipsaws As Traders Target Extreme Volatility" (6h ago, YELLOW, MARKET WIRE)
• Simply Wall St, "Apimeds Pharmaceuticals US (NYSEAM:APUS) - Stock Analysis" (9h ago, YELLOW, MARKET WIRE)
• Benzinga, "12 Health Care Stocks Moving In Tuesday's Intraday Session" (12h ago, YELLOW, MARKET WIRE)
• StocksToTrade, "APUS Stock Whipsaws As Traders Zero In On Volatility And Cash Burn" (15h ago, YELLOW, MARKET WIRE)

Risk watch items from the headlines are volatility and cash burn. The Butterfly Supply-Chain Graph reports no supply-chain relationships and no proprietary signals.

• What specific product or pipeline drives the FY 2025 operating loss of $-11.9M, and what is the commercial timeline?
• What is the source of the conflicting market capitalization figures ($5.0M in market data versus $0.0B in the profile)?
• What is the cash runway given $1.6M in cash against $-9.0M of FY 2025 free cash flow, and how is the gap financed?
• Why is the reported debt listed as N/A when Debt/Equity is cited at 0.5?
• What drove the 52-week range from $1.51 to $59.7, and what share-count or corporate events explain that move?